Haemonetics (HAE)
(Delayed Data from NYSE)
$90.99 USD
+3.33 (3.80%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $91.00 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for Haemonetics Corporation falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 115.40 | 43.38 | 79.47 | 76.53 |
Depreciation/Amortization & Depletion | NA | 95.28 | 101.15 | 84.29 | 110.29 |
Net Change from Assets/Liabilities | NA | 25.50 | -15.18 | -59.68 | -84.56 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 36.88 | 42.91 | 4.73 | 55.96 |
Net Cash From Operating Activities | NA | 273.06 | 172.26 | 108.81 | 158.22 |
Property & Equipment | NA | -108.58 | -94.49 | -35.23 | -31.98 |
Acquisition/ Disposition of Subsidiaries | NA | -2.00 | 8.14 | -390.22 | -25.19 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | -33.21 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -143.79 | -86.35 | -425.44 | -57.18 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -67.98 | 6.55 | -37.17 | -162.98 |
Issuance (Repayment) of Debt | NA | -9.63 | -17.50 | 478.13 | -13.13 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | -60.00 | 45.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -22.76 | -4.80 | -13.50 | -0.10 |
Net Cash from Financing Activities | NA | -100.36 | -15.75 | 367.45 | -131.21 |
Effect of Exchange Rate Changes | NA | -3.94 | -2.98 | 4.18 | -1.87 |
Net Change In Cash & Equivalents | NA | 24.97 | 67.19 | 54.99 | -32.04 |
Cash at Beginning of Period | NA | 259.50 | 192.31 | 137.31 | 169.35 |
Cash at End of Period | NA | 284.47 | 259.50 | 192.31 | 137.31 |
Diluted Net EPS | NA | 2.24 | 0.84 | 1.55 | 1.48 |
Fiscal Year End for Haemonetics Corporation falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 97.19 | 65.95 | 41.04 | 115.40 |
Depreciation/Amortization & Depletion | NA | 71.97 | 47.66 | 23.86 | 95.28 |
Net Change from Assets/Liabilities | NA | -87.30 | -20.23 | -51.70 | 25.50 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 35.81 | 24.84 | 5.89 | 36.88 |
Net Cash From Operating Activities | NA | 117.67 | 118.21 | 19.09 | 273.06 |
Property & Equipment | NA | -55.35 | -33.40 | -9.26 | -108.58 |
Acquisition/ Disposition of Subsidiaries | NA | -243.85 | 0.00 | 0.00 | -2.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | -10.13 | -7.00 | -6.00 | -33.21 |
Net Cash from Investing Activities | NA | -309.33 | -40.40 | -15.26 | -143.79 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 7.11 | 4.19 | 3.50 | -67.98 |
Issuance (Repayment) of Debt | NA | 101.25 | -5.25 | -1.75 | -9.63 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -6.70 | -6.71 | -2.35 | -22.76 |
Net Cash from Financing Activities | NA | 101.66 | -7.77 | -0.60 | -100.36 |
Effect of Exchange Rate Changes | NA | -0.48 | -3.51 | -1.97 | -3.94 |
Net Change In Cash & Equivalents | NA | -90.49 | 66.54 | 1.25 | 24.97 |
Cash at Beginning of Period | NA | 284.47 | 284.47 | 284.47 | 259.50 |
Cash at End of Period | NA | 193.98 | 351.01 | 285.72 | 284.47 |
Diluted Net EPS | NA | 0.61 | 0.48 | 0.80 | 0.58 |